print_label | resize_label

AstraZeneca Access 360 provides you with free personal support to help you so you can have access to the medicines you need. We will make every effort to work with you to help you navigate complicated financial and insurance questions. Our knowledgeable and compassionate Reimbursement Counselors will try to provide you with the support you need so you don't have to miss a dose.

AstraZeneca Access360AstraZeneca Access360AstraZeneca Access360

We can help you with:

  • Complicated insurance questions and processes
  • Locating a pharmacy
  • Finding the financial help that is right for you
  • Providing information about support programs that you may be eligible for if you don't have, or have been denied, insurance coverage

Call today to meet your AstraZeneca Reimbursement Counselor at 844-ASK-A360 (844-275-2360)844-ASK-A360 (844-275-2360) Monday - Friday 8AM-8PM ET.

For additional information, visit www.MyAccess360.com

If you’re without prescription coverage or can’t afford your medication, AstraZeneca may be able to help. Please visit www.AstraZeneca-us.com for more information.

TAGRISSO Connects: a patient support program

TAGRISSO™ (osimertinib) Connects logo TAGRISSO™ TAGRISSO™ (osimertinib) Connects logo

TAGRISSO Connects is an AstraZeneca educational program designed to give you support during your treatment with TAGRISSO.

When you sign up for TAGRISSO Connects, you may receive e-mails with discussion points to help you talk about your therapy with your healthcare team.

  • A discussion guide to help talk about lung cancer and your therapy with your healthcare team
  • A series of informative e-mails and ongoing support to help you throughout treatment
  • Educational newsletters about TAGRISSO that can be shared with your friends or family

What is metastatic EGFR T790M NSCLC?

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. About 85% to 90% of lung cancers are NSCLC. There are three main subtypes: squamous cell, adenocarcinoma, and large cell. The cells in these subtypes differ in size, shape, and chemical makeup when looked at under a microscope.

EGFR, or epidermal growth factor receptor, is a type of protein found on the surface of cells in the body. However, when this protein is mutated and becomes too active, it can lead to cancer growth. Approximately 15% of patients with advanced NSCLC have tumors that are EGFR mutation positive.

T790M is an acquired mutation that develops in response to first-line treatment of the EGFR mutation. It is observed in approximately 2 out of 3 tumors that progress, and is detected when a doctor performs another test after disease progression occurs, or when a tumor starts to grow again.Learn more >>

What does it mean to be EGFR positive?

EGFR, or epidermal growth factor receptor, is a type of protein found on the surface of cells in the body. However, when this protein is mutated and becomes active, it can lead to cancer growth. Approximately 15% of patients with advanced NSCLC have tumors that are EGFR mutation positive. Learn more >>

What is the T790M mutation?

T790M is an acquired mutation that develops in response to first-line treatment of the EGFR mutation. It is observed in approximately 2 out of 3 tumors that progress, and is detected when a doctor performs another test after disease progression occurs, or when a tumor starts to grow again. Learn more >>

What is TAGRISSO?

TAGRISSO is a prescription medicine used to treat non-small cell lung cancer (NSCLC). TAGRISSO may be used when your NSCLC has spread to other parts of the body and:

  • has a certain type of abnormal epidermal growth factor receptor (EGFR) gene (T790M), and
  • you have had previous treatment with an EGFR tyrosine kinase inhibitor medicine and it has stopped working Learn more >>

How do I take TAGRISSO?

TAGRISSO is a tablet you take once a day. Take it with or without food, at the same time every day. Swallow your TAGRISSO tablet whole, with water. Learn more >>

What are the side effects of TAGRISSO?

TAGRISSO may cause serious side effects, including:

  • lung problems. TAGRISSO may cause lung problems that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your doctor right away if you have any new or worsening lung symptoms, including trouble breathing, shortness of breath, cough, or fever.
  • heart problems, including heart failure. TAGRISSO may cause heart problems that may lead to death. Your doctor should check your heart function before you start taking TAGRISSO and during treatment. Call your doctor right away if you have any of the following signs and symptoms of a heart problem: feeling like your heart is pounding or racing, shortness of breath, swelling of your ankles and feet, feeling lightheaded.

The most common side effects of TAGRISSO in clinical trials were diarrhea and skin reactions such as rash, dry skin, and changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from nailbed, and shedding of nails.Learn more >>

What may TAGRISSO do for me?

Your metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC) has changed in a way that TAGRISSO was designed to help treat.

When you were first diagnosed, the biopsy of your tumor determined that you had NSCLC, and a test confirmed that the cancer cells had the EGFR (epidermal growth factor receptor) mutation. Your treatment included a targeted therapy—specifically a tyrosine kinase inhibitor (TKI). The TKI therapy was designed to attach to the EGFR proteins with the goal of slowing down the growth of the cancer cells or making the tumors smaller. This line of therapy may have helped your tumors to shrink, or stay the same size, for a period of time.

You’re not alone. In people who have EGFR mutation-positive NSCLC and have progressed on certain EGFR TKI therapies, the T790M mutation is related to progression of the disease in almost 2 out of 3 cases. So AstraZeneca has created a treatment called TAGRISSO that targets the T790M mutation. It may help shrink tumors—and your doctor has prescribed it for you. Learn more >>

What should I tell my doctor before starting TAGRISSO?

Before taking TAGRISSO, tell your doctor about all of your medical conditions, including if you:

  • have lung or breathing problems
  • have heart problems, including a condition called long QTc syndrome
  • have problems with your electrolytes, such as sodium, potassium, calcium or magnesium
  • are pregnant or plan to become pregnant. TAGRISSO can harm your unborn baby. Tell your doctor right away if you become pregnant during TAGRISSO treatment or think you may be pregnant.
    • Females who are able to become pregnant should use an effective birth control during TAGRISSO treatment and for 6 weeks after the final TAGRISSO dose.
    • Males who have female partners that are able to become pregnant should use effective birth control during TAGRISSO treatment with TAGRISSO and for 4 months after the final TAGRISSO dose.
  • are breastfeeding or plan to breastfeed. It is not known if TAGRISSO passes into your breast milk. Do not breastfeed during TAGRISSO treatment and for 2 weeks after your final TAGRISSO dose. Talk to your doctor about the best way to feed your baby during this time.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Especially tell your doctor if you take a heart or blood pressure medicine.

Learn more >>

How do I tell people in my life that my cancer has progressed?

It may be difficult news to share, so it might help to just stick with the basics:

  • Your cancer started progressing
  • It became resistant to your previous treatment
  • You had a new test to uncover what type of resistance the tumors developed
  • The test showed that the cancer now has a specific mutation
  • Your doctor prescribed a medicine that specifically targets this new mutation.

Learn more>>

Are there any financial support programs for TAGRISSO?

AstraZeneca Access 360™ can answer questions about insurance coverage for TAGRISSO and connect you to affordability programs upon request. www.myaccess360.com/patients to learn more.

The following organizations are dedicated to educating and encouraging people with lung cancer, and they have resources available to help with your physical and emotional needs.

The American Cancer Society offers a variety of programs and resources.

www.cancer.org

1-800-227-2345

The Bonnie J. Addario Lung Cancer Foundation funds research, offers resources for patients, and raises awareness.

www.lungcancerfoundation.org

1-650-598-2857

Free To Breathe is a partnership of lung cancer patients, advocates, and professionals.

www.freetobreathe.org

1-608-833-7905

GRACE, the Global Resource for Advancing Cancer Education, provides news and information from cancer experts on cancer management and treatment.

www.cancergrace.org

1-888-501-1025

 

Lung Cancer Alliance supports research and education nationwide.

www.lungcanceralliance.org

1-800-298-2436

Lungcancer.org by CancerCare® offers free services and support for people with lung cancer, including support groups, financial assistance, and more.

www.lungcancer.org

1-800-813-(HOPE)4673

LUNGevity helps people through support, education, and research.

www.lungevity.org

1-312-407-6100

LVNG With Lung Cancer is a community of people like you who are inspiring each other to face each day with authenticity and hope.

www.LVNG.com www.facebook.com/lvngwith www.instagram.com/lvngwith

1-800-236-9933

Cancer

A group of many diseases that happen when cells in the body grow and divide out of control, and older cells don’t die out as they should.

Cancer cells

Cells that make copies of themselves when they shouldn’t and spread throughout the body, interfering with normal cells.

Cardiomyopathy

Diseases of the heart muscle that cause it to become enlarged, rigid or thick, due to a variety of causes and symptoms.

Changes in nails

Redness, tenderness, pain, inflammation, brittleness, separation from nailbed, and shedding of nails, that may occur as a side effect.

Chemotherapy

Drug therapy that can kill cancer cells. Chemotherapy is not designed to affect a specific process, so it may affect both healthy and cancerous cells.

Diarrhea

Loose watery stools that come more than three times in a day, along with bloating, cramps and an urgent need to use the bathroom.

DoR: Duration of response

The amount of time that a cancer responds to a specific treatment, from the time that the cancer stops growing to the time that it begins to progress again.

Dry skin

Abnormal dryness, sometimes with itching, rash, or skin fissures, that may occur as a side effect.

EGFR: Epidermal growth factor receptor

is a protein that may be found on the surface of some cells. When mutated, EGFR plays a role in causing cancer cells to grow and spread as tumors.

Embryo-fetal toxicity

When a medicine has the ability to harm an unborn baby.

ILD: Interstitial lung disease

A condition that damages the lungs with swelling (inflammation) and scarring, causing shortness of breath and/or difficult breathing.

Median

The middle number in a group of numbers arranged from lowest to highest.

Mutation

A change that happens in the DNA of a cell. Not all mutations cause cancer, but all cancers are thought to be the result of mutations.

NSCLC: Non-small cell lung cancer

is one of two main types of lung cancer, and is the most common.

Progression

When cancer cells grow or spread.

Protein

A large molecule that is important for many of the processes that happen in and around cells in the body.

QTc interval prolongation

A problem with the heart’s electrical activity that can cause the heart to beat too fast, too slow, or with an irregular rhythm.

Rash

Irritated, itchy, red, and/or swollen skin.

Resistance

When cancer cells are no longer harmed by the drugs used to kill or disrupt them. Tumors can be resistant from the start or become resistant in the course of treatment.

Side effect

An unwanted reaction in the body from a treatment or therapy.

Targeted therapy, targeted treatment

A cancer treatment that is designed to affect a specific activity in the cells.

TKI: A tyrosine kinase inhibitor

is a substance that prevents enzymes called tyrosine kinases from working. These enzymes are involved in the growth and division of cancer cells. TKIs are a type of targeted therapy.

Tumor

A mass or lump made up of cancer cells.

T790M

A secondary mutation that happens in tumors that are EGFR mutation positive. When T790M is present, the cells can develop a resistance to the TKI being used as a treatment.

TAGRISSO may cause serious side effects, including:

  • lung problems. TAGRISSO may cause lung problems that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your doctor right away if you have any new or worsening lung symptoms, including trouble breathing, shortness of breath, cough, or fever

  • heart problems, including heart failure. TAGRISSO may cause heart problems that may lead to death. Your doctor should check your heart function before you start taking TAGRISSO and during treatment as needed. Tell your doctor right away if you have any of the following signs and symptoms of a heart problem: feeling like your heart is pounding or racing, shortness of breath, swelling of your ankles and feet, feeling lightheaded

  • eye problems. TAGRISSO may cause eye problems. Tell your doctor right away if you have symptoms of eye problems which may include watery eyes, sensitivity to light, eye pain, eye redness, or vision changes. Your doctor may send you to see an eye specialist (ophthalmologist) if you get eye problems with TAGRISSO

Before taking TAGRISSO, tell your doctor about all of your medical conditions, including if you:

  • have lung or breathing problems

  • have heart problems, including a condition called long QTc syndrome

  • have problems with your electrolytes, such as sodium, potassium, calcium or magnesium

  • have a history of eye problems

  • are pregnant or plan to become pregnant. TAGRISSO can harm your unborn baby. Tell your doctor right away if you become pregnant during treatment with TAGRISSO or think you may be pregnant.

    • Females who are able to become pregnant should use effective birth control during treatment with TAGRISSO and for 6 weeks after the final dose of TAGRISSO
    • Males who have female partners that are able to become pregnant should use effective birth control during treatment with TAGRISSO and for 4 months after the final dose of TAGRISSO
  • are breastfeeding or plan to breastfeed. It is not known if TAGRISSO passes into your breast milk. Do not breastfeed during treatment with TAGRISSO and for 2 weeks after your final dose of TAGRISSO. Talk to your doctor about the best way to feed your baby during this time

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Especially tell your doctor if you take a heart or blood pressure medicine.

The most common side effects of TAGRISSO are:

  • diarrhea

  • rash

  • dry skin

  • changes in your nails, including: redness, tenderness, pain, inflammation, brittleness, separation from nailbed, and shedding of nails

  • tiredness

Tell your doctor if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of TAGRISSO. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.1-800-FDA-1088.

What is TAGRISSO?

TAGRISSO is a prescription medicine used to treat non-small cell lung cancer... read more (NSCLC). TAGRISSO may be used when your non-small cell lung cancer has spread to other parts of the body and:

  • has a certain type of abnormal epidermal growth factor receptor (EGFR) gene, called T790M, and

  • you have had previous treatment with an EGFR tyrosine kinase inhibitor medicine and it has stopped working

Your doctor will perform a test to make sure that TAGRISSO is right for you.

It is not known if TAGRISSO is safe and effective in children.

Please see accompanying full Prescribing Information including Patient Information.